Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:HYFT NASDAQ:IBIO NASDAQ:MLND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.16+1.2%$4.27$1.21▼$3.81$102.74M0.68261,100 shs3.96 million shsHYFTMindWalk$1.58+3.9%$1.47$0.99▼$3.25$72.93M0.79364,616 shs391,031 shsIBIOiBio$1.67+5.0%$1.73$0.56▼$3.82$82.96M1.26760,780 shs1.51 million shsMLNDMillendo Therapeutics$1.56$4.00$0.92▼$16.95$29.71M0.481.52 million shs152,321 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.38%-7.01%-13.84%+30.06%+117.46%HYFTMindWalk+3.95%+3.27%-7.60%+47.66%+157,999,900.00%IBIOiBio+5.03%-1.18%-11.17%-5.11%+166,999,900.00%MLNDMillendo Therapeutics0.00%0.00%0.00%-9.83%-77.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.16+1.2%$4.27$1.21▼$3.81$102.74M0.68261,100 shs3.96 million shsHYFTMindWalk$1.58+3.9%$1.47$0.99▼$3.25$72.93M0.79364,616 shs391,031 shsIBIOiBio$1.67+5.0%$1.73$0.56▼$3.82$82.96M1.26760,780 shs1.51 million shsMLNDMillendo Therapeutics$1.56$4.00$0.92▼$16.95$29.71M0.481.52 million shs152,321 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.38%-7.01%-13.84%+30.06%+117.46%HYFTMindWalk+3.95%+3.27%-7.60%+47.66%+157,999,900.00%IBIOiBio+5.03%-1.18%-11.17%-5.11%+166,999,900.00%MLNDMillendo Therapeutics0.00%0.00%0.00%-9.83%-77.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AHYFTMindWalk 2.60Moderate Buy$5.00216.46% UpsideIBIOiBio 3.13Buy$5.00199.40% UpsideMLNDMillendo Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MLND, AADI, IBIO, and HYFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026IBIOiBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/8/2026IBIOiBio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/8/2026IBIOiBio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/5/2026IBIOiBio B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/19/2026HYFTMindWalk HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.004/16/2026HYFTMindWalk JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.004/15/2026HYFTMindWalk JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/9/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/27/2026IBIOiBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M4.10N/AN/A$4.29 per share0.97HYFTMindWalk$17.59M4.15N/AN/A$0.37 per share4.27IBIOiBio$400K207.41N/AN/A$0.90 per share1.86MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/AHYFTMindWalk-$21.69M-$0.20N/AN/AN/A-66.79%-69.37%-39.74%N/AIBIOiBio-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%9/4/2026 (Estimated)MLNDMillendo Therapeutics-$36.41MN/AN/AN/AN/AN/A-91.03%-72.44%N/ALatest MLND, AADI, IBIO, and HYFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q3 2026IBIOiBio-$0.06-$0.07-$0.01-$0.06$0.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AHYFTMindWalkN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54HYFTMindWalk0.213.743.64IBIOiBioN/A11.8811.88MLNDMillendo TherapeuticsN/A6.396.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%HYFTMindWalk6.70%IBIOiBio7.90%MLNDMillendo TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%HYFTMindWalk6.83%IBIOiBio2.75%MLNDMillendo TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataHYFTMindWalk8046.16 million43.00 millionN/AIBIOiBio10049.68 million48.31 millionN/AMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableMLND, AADI, IBIO, and HYFT HeadlinesRecent News About These CompaniesTheory of MindOctober 23, 2024 | psychologytoday.comPFDA tells oncology companies how to run multi-regional cancer trials with a US approval in mindSeptember 17, 2024 | endpts.comENRG Therapeutics gets grant to test mitochondria-targeting ALS therapySeptember 13, 2024 | alsnewstoday.comAAstellas pushes non-hormonal menopause drug into phase 3September 6, 2024 | pharmaphorum.comPRelease Therapeutics Secures CHF 3.3 Million in Seed FundingAugust 6, 2024 | tmcnet.comMind & BodyAugust 1, 2024 | greatergood.berkeley.eduGA lifesaving therapy for children with a rare disease is now the world’s most expensive drug, raising questions about accessMarch 20, 2024 | msn.comMind Medicine sends psychedelic stocks higher after FDA status for LSD formulationMarch 7, 2024 | msn.comClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private PlacementJanuary 11, 2024 | markets.businessinsider.comWhy Is Clearmind Medicine (CMND) Stock Up 50% Today?December 5, 2023 | msn.comMaxim Group Maintains Their Buy Rating on Mind Medicine (MMED)November 6, 2023 | markets.businessinsider.comWhat to Look For in the Pipeline, Misconceptions of Drug Approvals and More of ‘What’s on the Mind’ of Jeffrey CasbergJune 15, 2023 | managedhealthcareexecutive.comMNumab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 ProgramMay 15, 2023 | eagletribune.comEMindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy ParticipantsMay 10, 2023 | sports.yahoo.comExpert Ratings for Decibel TherapeuticsMarch 15, 2023 | benzinga.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2022 Earnings Call TranscriptDecember 29, 2022 | insidermonkey.comClearmind Medicine Announces Shareholders Meeting ResultsDecember 29, 2022 | yahoo.comClearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in IndiaJune 3, 2022 | finance.yahoo.comDTx Pharma Appoints Michael Huang, MD as Chief Medical OfficerMay 31, 2022 | finance.yahoo.comClearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use DisorderMay 26, 2022 | koin.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLND, AADI, IBIO, and HYFT Company DescriptionsAadi Bioscience NASDAQ:AADI$4.16 +0.05 (+1.22%) As of 06/26/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.MindWalk NASDAQ:HYFT$1.58 +0.06 (+3.95%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.57 -0.01 (-0.63%) As of 06/26/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.iBio NASDAQ:IBIO$1.67 +0.08 (+5.03%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.66 -0.01 (-0.72%) As of 06/26/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.Millendo Therapeutics NASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
